Forecast
The analysts' average price target is €79.74 (+30.29%). The median is €76.10 (+24.35%).
| Buy |
Â
26 |
| Hold |
Â
10 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Globus Medical receives CE marking for imaging system Excelsius3D and begins EU/UK commercialization
Globus Medical has received CE marking for commercial distribution of its mobile imaging system Excelsius3D in the European Union and the United Kingdom. Excelsius3D combines 3D cone‑beam CT, 2D fluoroscopy and digital radiography and can be integrated into the robotic navigation system ExcelsiusGPS to enable intraoperative imaging and robot‑assisted navigation. The system was already cleared in the US in 2021 via 510(k); the stock rose slightly in after‑hours trading. » More on de.investing.com
Globus Medical acquires digital-health company Higgs Boson Health
Globus Medical announced the acquisition of Higgs Boson Health, a Durham (North Carolina)-based digital-health startup spun out of Duke University. Higgs Boson brings software developers and AI scientists and will be integrated into Globus Medical’s division for digital health technologies. The technology will become part of the “Surgical Intelligence” pillar and be used across the entire patient journey; financial details were not disclosed. » More on de.investing.com
Globus Medical exceeds revenue forecast in Q2, raises non‑GAAP earnings target
Globus Medical reported Q2 revenue of $789.6 million and a record non‑GAAP EPS of $1.34; GAAP EPS of $1.10 matched analysts’ estimates. Adjusted EBITDA margin rose to 35.4% and the company generated strong operating cash flow of $412.1 million in the first half of the year. Globus reaffirmed full‑year revenue guidance of $3.18–3.22 billion and raised its non‑GAAP EPS outlook to $4.95–5.05; the stock reacted positively in after‑hours trading. Management cited margin expansion, market‑share gains in spine and trauma, and continued investments in the product pipeline and enabling technologies. » More on de.investing.com
Madison Small Cap Fund sells Globus Medical after valuation surpasses its estimate
Madison Small Cap Fund liquidated its multi-year position in Globus Medical, saying the company's post-acquisition success and robotics adoption pushed market value above its intrinsic estimate. The fund cited a market cap near $12 billion and an intrinsic value of $85 per share versus a roughly $90 market price, and said it will reallocate to smaller opportunities. Fund performance and broader market context (value outperformance, AI/geopolitical volatility) were noted in the Q1 2026 letter. » More on finance.yahoo.com
Wells Fargo cuts price target on Globus Medical after strong Q1 results
Wells Fargo lowered its price target on Globus Medical to $103 from $104 while maintaining an Overweight rating despite the company reporting fiscal Q1 sales and EPS above consensus. Globus posted worldwide net sales of $759.9 million, up 27.0% (25.5% cc), and base business sales excluding Nevro of $677.2 million, up 13.2% (11.2% cc). Management cited record Q1 earnings, organic revenue growth driven by share gains and procedural volume in core spine, and expansion of the customer base through Enabling Technologies. » More on finance.yahoo.com
Financials
In the last quarter, Globus Medical had revenue of €674.25M and net profit of €124.63M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 674.25M | 2.89% |
| Gross profit | 468.62M | 13.00% |
| Net profit | 124.63M | 22.94% |
| EBITDA | 223.93M | 22.16% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €8.08B |
Number of shares | 132.47M |
52-week high/low | €92.41 - €60.72 |
| Dividends | No |
Beta | 0.96 |
P/E ratio | 16.16 |
PEG ratio | 0.49 |
P/B ratio | 1.87 |
P/S ratio | 2.82 |
Company profile
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
| Name | Globus Medical |
| CEO | Keith W. Pfeil |
| Headquarters | Audubon,
pa USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 08/03/2012 |
| Employees | 6,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | GMED |
Frankfurt | GM0N.F |
DĂĽsseldorf | GM0N.DU |
MĂĽnchen | GM0N.MU |